Get started
Author

Christian Schauer

Atezolizumab Combined With Bevacizumab and Platinum-Based Therapy for Platinum-Sensitive Ovarian Cancer: Placebo-Controlled Randomized Phase III ATALANTE/ENGOT-ov29 Trial
2023 · Jean-Emmanuel Kurtz, Eric Pujade-Lauraine, et al. · Journal of Clinical Oncology · 113
Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial
2019 · Ignace Vergote, Giovanni Scambia, et al. · The Lancet Oncology · 88
PDF
Topical Imiquimod Versus Surgery for Vulvar Intraepithelial Neoplasia:A Multicentre, Randomised, Phase 3, Non-Inferiority Trial
2021 · Gerda Trutnovsky, Olaf Reich, et al. · The Lancet · 55
Impact of secondary cytoreductive surgery on survival in patients with platinum sensitive recurrent ovarian cancer: Analysis of the CALYPSO trial
2014 · Chee Khoon Lee, Sarah Lord, et al. · Gynecologic Oncology · 55
Prophylactic salpingectomy for prevention of ovarian cancer at the time of elective laparoscopic cholecystectomy
2020 · G Tomasch, M Lemmerer, et al. · British journal of surgery · 54
PDF
A prognostic nomogram to predict overall survival in patients with platinum-sensitive recurrent ovarian cancer
2012 · C.K. Lee, R.J. Simes, et al. · Annals of Oncology · 42
PDF
Pros and cons of intraperitoneal chemotherapy in the treatment of epithelial ovarian cancer.
2009 · Alain G Zeimet, Daniel Reimer, et al. · PubMed · 34
Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
2023 · Raphaël Leman, Etienne Muller, et al. · Clinical Cancer Research · 30
PDF
INOVATYON/ ENGOT-ov5 study: Randomized phase III international study comparing trabectedin/pegylated liposomal doxorubicin (PLD) followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line
2023 · N. Colombo, A. Gadducci, et al. · British Journal of Cancer · 27
PDF
The time of diagnosis impacts surgical management but not the outcome of patients with gallbladder Carcinoma
2009 · F Löhe, G Meimarakis, et al. · European journal of medical research · 23
PDF
Risk of endometrial cancer in asymptomatic postmenopausal patients with thickened endometrium: data from the FAME-Endo study: an observational register study
2018 · Lukas Hefler, Judith Lafleur, et al. · Archives of Gynecology and Obstetrics · 22
AGO Austria recommendations for genetic testing of patients with ovarian cancer
2015 · Christian Marth, Michael Hubalek, et al. · Wiener klinische Wochenschrift · 14
PDF
Pegylated liposomal doxorubicin and carboplatin (C-PLD) versus paclitaxel and carboplatin (C-P) in platinum-sensitive ovarian cancer (OC) patients (pts): Treatment at recurrence and overall survival (OS) final analysis from CALYPSO phase III GCIG trial.
2011 · C. Marth, J. Alexandre, et al. · Journal of Clinical Oncology · 13
AGO Austria recommendation on screening and diagnosis of Lynch syndrome (LS)
2017 · Alain G. Zeimet, Harald Mori, et al. · Archives of Gynecology and Obstetrics · 12
PDF
Maintenance olaparib plus bevacizumab (bev) after platinum-based chemotherapy plus bev in patients (pts) with newly diagnosed advanced high-grade ovarian cancer (HGOC): Efficacy by BRCA1 or BRCA2 mutation in the phase III PAOLA-1 trial.
2020 · Domenica Lorusso, Jean-Pierre Lotz, et al. · Journal of Clinical Oncology · 11
Axillary lymph node status and invasive lobular breast cancer
2023 · Sabine Danzinger, Karin Pöckl, et al. · Wiener klinische Wochenschrift · 10
PDF
BRCA1 and RAD51 methylation impact on outcome in patients with advanced ovarian cancer: A PAOLA-1 ancillary study.
2023 · Helene Blons, Justine Abdelli, et al. · Journal of Clinical Oncology · 9
A deep learning solution for detection of homologous recombination deficiency in ovarian cancer using low pass whole-genome sequencing: Evaluation of the analytical performance.
2022 · Adrien Buisson, Pierre Saintigny, et al. · Journal of Clinical Oncology · 8
2022-RA-913-ESGO Clinical performance evaluation of a novel deep learning solution for homologous recombination deficiency detection
2022 · Adrien Buisson, Pierre Saintigny, et al. · International Journal of Gynecological Cancer · 5
PDF
Prophylactic long-acting granulocyte-colony stimulating factors (G-CSF) in gynecologic malignancies: an oncologic expert statement
2015 · Edgar Petru, Christian F. Singer, et al. · Wiener Medizinische Wochenschrift · 5
Carboplatin and Nonpegylated Liposomal Doxorubicin inPrimary Advanced or Recurrent Endometrial Cancer
2015 · Birgit Volgger, Alain G. Zeimet, et al. · International Journal of Gynecological Cancer · 5
Safety and quality of life with maintenance olaparib plus bevacizumab in older patients with ovarian cancer: subgroup analysis of PAOLA‑1/ENGOT-ov25
2024 · Coline Montégut, Claire Falandry, et al. · The Oncologist · 4
Can Morphology and Immune Infiltration Predict the Homologous Recombination Deficiency Status in Newly Diagnosed High-Grade Serous Ovarian Carcinoma?: Lessons From the PAOLA-1/ENGOT-ov25 Trial, a GINECO Study
2024 · Amel Kime, Guillaume Bataillon, et al. · Archives of Pathology & Laboratory Medicine · 4
Blinded-assessment of a solution to evaluate olaparib maintenance treatment efficacy in patients with ovarian cancer from the GINECO/ENGOT PAOLA-1 trial.
2023 · Adrien Buisson, Pierre Saintigny, et al. · Journal of Clinical Oncology · 4
PDF
167 Safety and quality of life of first-line maintenance olaparib plus bevacizumab in older patients with advanced ovarian cancer in the PAOLA-1 trial
2021 · C. Montégut, C. Falandry, et al. · International Journal of Gynecological Cancer · 3
PDF
Works count: 71
Citation count: 656
H-index: 13
I10-index: 16
Year
Topic
Type